Delivery of Soluble Ferric Pyrophosphate (SFP) Via the Dialysate to Maintain Iron Balance in Hemodialysis Patients

Stopped early · Not applicable · Has a placebo group

Conditions studied: End Stage Renal Disease (ESRD)

In brief

In maintenance hemodialysis patients, regular administration of parenteral iron by addition of soluble ferric pyrophosphate (SFP) to the dialysate, when compared to conventional dialysate, is effective in preventing the development of iron deficiency, thereby maintaining hemoglobin level; is clinically safe and does not lead to oxidative stress or inflammation.

Key facts

Study ID

NCT00604565

Run by

Charles Drew University of Medicine and Science

People needed

11

Starts

2008-01-01

Expected to finish

2010-12-01

Last updated by the study team

2015-08-31

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may not qualify if…

• Subjects with absolute iron deficiency at the time of enrollment In hemodialysis subjects "absolute iron deficiency"
• Subjects with a current malignancy involving sites other than skin.
• Subjects with a history of drug or alcohol abuse within the last 6 months

Where it is running

• RAI — Los Angeles, California, United States
• University of Louisville Kidney Disease Program — Louisville, Kentucky, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.